A carregar...
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab....
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6405333/ https://ncbi.nlm.nih.gov/pubmed/30530801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-10-879429 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|